Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema

Zohar Habot-Wilner, Nir Sorkin, Dafna Goldenberg, Anat Loewenstein, Michaella Goldstein

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report the long-term outcome of an intravitreal dexamethasone drug delivery system (DEX-DDS) injection for noninfectious uveitic macular edema. Methods: This was a retrospective study of 8 eyes (7 patients). Results: The mean follow-up time was 17.3 months. Macular edema resolved in all eyes at 3.9 weeks (range 1-6.9) postinjection. The central point thickness improved from 612 ± 143 to 250 ± 55 μm (p < 0.05). The mean best corrected visual acuity improved by 0.25 logMAR (p < 0.05) at 3.9 weeks (range 1-6.9) postinjection. In 5 eyes, macular edema did not recur after a mean follow-up of 14.5 months. In 3 eyes, macular edema relapsed after 4.7 months (range 3.6-6.3) and resolved again following further injections. Two eyes developed intraocular pressure elevation, which was well controlled with topical treatment. Conclusions: Intravitreal DEX-DDS injections resulted in resolution of macular edema and visual acuity improvement. Some eyes required repeated injections, but most eyes achieved long-term resolution. No significant complications were noticed.

Original languageEnglish
Pages (from-to)77-82
Number of pages6
JournalOphthalmologica
Volume232
Issue number2
DOIs
StatePublished - 2014

Keywords

  • Cystoid macular edema
  • Dexamethasone intravitreal implant
  • Ozurdex
  • Spectral domain optical coherence tomography
  • Uveitic macular edema
  • Uveitis

Fingerprint

Dive into the research topics of 'Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema'. Together they form a unique fingerprint.

Cite this